



## Review article

# Autoimmune manifestations in patients with multiple myeloma and monoclonal gammopathy of undetermined significance<sup>☆</sup>



Alexei Shimanovsky<sup>a,\*</sup>, Argote J. Alvarez<sup>b</sup>, Shruti Murali<sup>b</sup>, Constantin A. Dasanu<sup>c</sup>

<sup>a</sup> Department of Hematology and Oncology, University of Connecticut Health Science Center, Farmington, CT, USA

<sup>b</sup> Department of Medicine, University of Connecticut Health Science Center, Farmington, CT, USA

<sup>c</sup> Lucy Curci Cancer Center, Eisenhower Medical Center, Rancho Mirage, CA, USA

## ARTICLE INFO

## Article history:

Received 21 February 2016

Received in revised form 15 May 2016

Accepted 23 May 2016

Available online 25 May 2016

## ABSTRACT

**Background:** Multiple myeloma (MM) and its precursor, monoclonal gammopathy of undetermined significance (MGUS), have been linked with several autoimmune conditions in the medical literature. Yet, significance of these associations is not well understood.

**Methods:** Herein, we provide a comprehensive literature review on autoimmune disorders identified in patients with MM and MGUS. Most relevant papers were identified via searching the PubMed/Medline and EMBASE databases for articles published from inception until May 1, 2016.

**Findings:** Scientific literature on autoimmune conditions in patients with MM and MGUS consists of several case series and a multitude of case reports. Our analysis suggests an increased prevalence of autoimmune conditions in patients with MM and monoclonal gammopathy of undetermined significance (MGUS), including various autoimmune hematologic and rheumatologic conditions among other entities. Conversely, persons with various autoimmune conditions tend to have a higher prevalence of MGUS and MM than the general population.

**Conclusions:** Future research is required to explore further the link between MGUS/MM and autoimmune disorders. Inflammation in the setting of autoimmunity may serve as a trigger for MGUS and MM. In addition, a common genetic susceptibility for developing both an autoimmune disease and MM/MGUS might also exist. Autoimmune hematologic and rheumatologic diseases may pose important clinical problems for the MM patients. Therefore, a catalogue of these problems is important so that physicians are able to consider, identify and address them promptly.

© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

## Contents

1.	Introduction . . . . .	13
2.	Materials and methods . . . . .	13
3.	Overview and pathophysiology of autoimmunity and multiple myeloma . . . . .	13
4.	Autoimmune hematologic conditions in multiple myeloma . . . . .	13
4.1.	Pernicious anemia . . . . .	13
4.2.	Autoimmune hemolytic anemia (AIHA) . . . . .	14
4.3.	Pure red cell aplasia . . . . .	14
4.4.	Immune thrombocytopenia . . . . .	14
4.5.	Autoimmune neutropenia . . . . .	14
5.	Rheumatologic disorders in multiple myeloma . . . . .	14
5.1.	Rheumatoid arthritis . . . . .	14
5.2.	Systemic lupus erythematosus . . . . .	14
5.3.	Dermatomyositis and polymyositis . . . . .	15

<sup>☆</sup> We certify that we do not have any affiliation with or financial involvement in any organization or entity with a direct financial interest in the subject matter or materials discussed in the manuscript (e.g., employment, consultancies, stock ownership, honoraria, and expert testimony). We do not have any commercial or proprietary interest in any drug, device, or equipment mentioned in the article below. No financial support was used for this work. No previously published figures or tables were used in this paper. We certify sufficient participation of each author in the conception, design, analysis, interpretation, writing, revising, and approval of the manuscript. – The Authors

\* Corresponding author at: Department of Medicine, University of Connecticut Health Center, 263 Farmington Ave, Farmington, CT 06030, USA.

5.4. Sjogren's syndrome . . . . .	15
5.5. Ankylosing spondylitis . . . . .	15
5.6. Leukocytoclastic vasculitis . . . . .	15
6. Autoimmune neurologic disorders in multiple myeloma . . . . .	15
7. Immunomodulatory drugs and multiple myeloma . . . . .	16
8. Other autoimmune disorders in multiple myeloma . . . . .	16
9. MGUS and autoimmunity . . . . .	16
10. Discussion and conclusions . . . . .	16
Transparency document . . . . .	17
Conflict of interest . . . . .	17
References . . . . .	17

## 1. Introduction

Multiple myeloma (MM) is a clonal malignancy of plasma cells characterized by an overproduction of monoclonal antibodies. Clinically, this entity is characterized by skeletal lesions, anemia, hypercalcemia and renal failure. According to the United States Surveillance, Epidemiology and End Results (SEER), the incidence of MM is 6.1/100,000 people per year and increases to 30.4/100,000 people per year in those older than 65 years. The median age of diagnosis of MM is 71 years in whites, and 67 years in blacks [1]. As a rule, monoclonal gammopathy of undetermined significance (MGUS) precedes MM and carries an average 1% annual risk of progression to MM or other lymphoproliferative disorder [2]. While the etiology of both MGUS and MM remains unknown, risk factors such as advanced age, family history, male gender and environmental factors have been present in both conditions [3].

Several studies link MM with autoimmune disorders; however, the data has not yet been fully analyzed or systematized. Herein, we review comprehensively autoimmune conditions that have been associated with MM and MGUS in the medical literature.

## 2. Materials and methods

We performed a systematic search on PUBMED/MEDLINE, EMBASE and foreign articles published from inception to May 1, 2016. We searched for papers using the following keywords: 'multiple myeloma' and 'monoclonal gammopathy of undetermined significance' with each of the following keywords: 'autoimmune', 'autoimmunity', 'autoimmune hemolytic anemia', 'immune thrombocytopenia', 'vasculitis', 'polyarthritits', 'rheumatoid arthritis', 'rheumatologic disease', 'nephrotic syndrome', 'autoimmune neutropenia', 'thrombocytopenia', 'pure red cell aplasia', 'systemic lupus erythematosus', 'Sjogren's syndrome', 'myasthenia gravis', 'multiple sclerosis' and 'inflammatory bowel disease'. Several articles were also obtained via cross-reference checking and "snowball" method, when databases different from PUBMED and MEDLINE were accessed.

## 3. Overview and pathophysiology of autoimmunity and multiple myeloma

Immune dysregulation plays a key role in lymphomagenesis. Of note, chronic autoimmune inflammatory conditions have been associated with lymphoproliferative disorders such as lymphoma and chronic lymphocytic leukemia [4–5].

Indeed, chronic inflammation plays an important role in the development of lymphoproliferative diseases and other cancers [6]. In fact, there is current interest in development of targeted therapies that aim to control inflammation, such as with the toll-like receptor (TLR) pathway. For survival, B-cells in multiple myeloma depend on inflammation pathways involving interleukin (IL)-6, IL-13, and Tumor Necrosis Factor (TNF)- $\alpha$ . Furthermore, TLR and TLR-ligands expressed by B lymphocytes promote their proliferation and survival [7]. Other important components that help maintaining a favorable microenvironment for

malignant B-cells in MM include the B-cell activating factor (BAFF) which participates in the activation of the nuclear factor  $\kappa$ -B (NF- $\kappa$ B), an important B-cell malignancy pathway [8].

In recent years, a number of reports and case studies have hinted at the association between plasma cell dyscrasias and autoimmune disorders [9]. Osserman and Takatsuki were the first ones to hypothesize that chronic antigen stimulation may trigger the development of plasma cell dyscrasias [10]. As a result, chronic immune stimulation may lead to the development of hematological malignancies by randomly introducing pro-oncogenic mutations in rapidly dividing cells, including plasma cells [11].

## 4. Autoimmune hematologic conditions in multiple myeloma

Anemia is almost invariably present patients with MM, either at diagnosis or as the disease progresses. The pathogenesis of anemia in MM is usually multifactorial, including a component anemia of inflammation due to myeloma itself, bone marrow replacement with malignant plasma cells and anemia of renal failure due to erythropoietin deficit. However, such entities as pernicious anemia, autoimmune hemolytic anemia and pure red cell aplasia have also been described in these patients (Table 1).

Thrombocytopenia occurs frequently in patients with plasma cell dyscrasias. The pathogenesis usually involves marrow replacement by the myeloma cells or treatment with anti-myeloma agents. Neutropenia in MM is often due to the use of traditional chemotherapy agents, immunomodulating agents and, less frequently, other agents. Notwithstanding, there are cases of immune thrombocytopenia and autoimmune neutropenia in MM patients described in the literature (Table 1).

### 4.1. Pernicious anemia

Pernicious anemia is characterized by an autoimmune destruction of gastric parietal cells and antibody-mediated inactivation of the intrinsic factor resulting in malabsorption of cobalamin (vitamin B12), thus leading to megaloblastic anemia. Some studies established that incidence of cobalamin deficiency in patients with IgA multiple myeloma and MGUS is approximately 13.6% (Table 1) [12]. Several publications, including meta-analysis studies, suggest that pernicious anemia may represent a risk factor for MM [9,13–14]. In addition, a recent case-control study found a 1.47 times increase in risk of developing MM in patients with pernicious anemia [13]. While the exact steps of pathogenesis of plasma cell dyscrasias in patients with pernicious anemia is not well described, several hypotheses exist. One of them favors occurrence of immune alterations and chromosome abnormalities in the bone marrow of patients with pernicious anemia [15]. Another one postulates that cobalamin deficiency may promote carcinogenesis and development of plasma cell dyscrasias by causing abnormal DNA methylation [16]. Indeed, aberrant DNA methylation patterns have been demonstrated in patients with MM [17].

**Table 1**  
Hematologic autoimmune disorders associated with multiple myeloma and MGUS in the literature.

Disease	Proposed mechanism	Epidemiology	Therapy	References
Pernicious anemia	Disruption of B12-mediated methylation	Increased prevalence of IgA MM/MGUS in these patients	Vitamin B12 therapy has not been proven to impact the multiple myeloma outcome	[9,12–17]
AIHA PRCA	Occurrence of auto-reactive B-cell clones Marrow precursor suppression by monoclonal antibody or paraprotein	Prevalence 4–10% Unknown	Improves after MM therapy Refractory to immunosuppression; improves with MM therapy	[18–22,88] [23–25]
ITP Evans' syndrome	Clonal autoantibody production Associated with MM and IgA monoclonal gammopathy	Unknown Unknown	May improve with MM therapy May improve with MM therapy	[27,28] [29–31]
AIN	Clonal expansion of light chain-restricted anti-neutrophil antibodies Can be induced by MM therapy (e.g. lenalidomide, etc.)	Rare	No change	[33–35]

AIHA: autoimmune hemolytic anemia. AIN: autoimmune neutropenia. ITP: immune thrombocytopenia. MM: multiple myeloma. PRCA: pure red cell aplasia, MGUS: Monoclonal gammopathy of undetermined significance.

#### 4.2. Autoimmune hemolytic anemia (AIHA)

Autoimmune hemolytic anemia (AIHA) is known to be associated with B-cell lymphoproliferative neoplasms. Some studies claim that 4% of patients MM also have AIHA [6,18], while others suggest that AIHA is only rarely associated with MM [19]. However, a more recent case series reported that 7 of the 66 (10.6%) MM cases were complicated by AIHA and carried red cell autoantibodies in their serum [20]. In addition, another 10 cases of AIHA associated with MM have been recently reported in literature [21]. Of those, seven patients had IgG myeloma and four - IgA myeloma [20–21]. Interestingly, one patient in this series had a biclonal (IgG2 and IgA) MM. With the exception of two patients with relapsed myeloma, all patients demonstrated remission of AIHA after therapy for myeloma [20–21]. While the pathogenesis of AIHA in MM is unclear, it has been hypothesized that significant immune disturbances may allow the development of clones that produce autoantibodies against erythrocyte surface antigens [22].

#### 4.3. Pure red cell aplasia

Pure red cell aplasia (PRCA) is an acquired autoimmune condition [23]. PRCA in patients with MM has traditionally been considered a rare occurrence. Recently, three case reports have described a PRCA associated with MM [24–26]. In all cases, the diagnosis of PRCA was made concurrently with the diagnosis of MM. Sarathy et al. described a patient with PRCA refractory to immunosuppressive therapy that improved only after the patient was treated with bortezomib [26]. This finding suggested that PRCA was secondary to MM.

#### 4.4. Immune thrombocytopenia

Immune thrombocytopenia (ITP) has been reported in patients with lymphoproliferative disorders such as chronic lymphocytic leukemia and non-Hodgkin's lymphoma (NHL). While uncommon, ITP is also described in patients with MM [27–28]. In a series of six patients, thrombocytopenia was the initial presentation in two, with myeloma being diagnosed at a later stage [27–28]. Although the pathogenesis of ITP in lymphoproliferative disorders is poorly understood, it has been proposed that intrinsic immune alterations promote generation of specific autoreactive platelet antibodies [27]. In addition, ITP can be associated with AIHA as Evans' syndrome, with hemolysis usually preceding thrombocytopenia [29]. Two cases of Evans' syndrome have been described in patients with MM/MGUS [30–31]. However, one of the cases occurred in a patient with extramedullary plasmacytoma, a relatively rare plasma cell tumor not uncommonly preceding MM. The patient had IgA monoclonal gammopathy in serum and urine which was consistent with the diagnosis of MM [30]. The diagnosis of Evans' syndrome in this case preceded the diagnosis of MM by four years.

Interestingly, the second case of Evans' syndrome was also described in a patient with IgA MGUS [31].

#### 4.5. Autoimmune neutropenia

Therapy for MM can result in neutropenia. For instance, lenalidomide-induced neutropenia occurs in up to 35% of patients [32]. Autoimmune neutropenia (AIN), characterized by the presence of autoantibodies directed against neutrophils and an absolute neutrophil count of less than 1500 cells/ $\mu$ L, rarely occurs secondary to myeloma itself [33]. Aryal et al. [34] have recently reported a rare case of AIN associated with MM [34]. The authors hypothesized that the cross talk between T- and B-cells in MM can induce a clonal T-cell expansion and T-cell receptor gene rearrangement leading to the development of AIN. Shastri et al. [35] identified the presence of a clonal expansion of lymphoid cells that led to light chain-restricted neutrophil-binding autoantibodies in patients with antibody-induced neutropenia.

### 5. Rheumatologic disorders in multiple myeloma

Increased prevalence of several rheumatologic conditions has been linked with multiple myeloma and MGUS (Table 2).

#### 5.1. Rheumatoid arthritis

Rheumatoid arthritis (RA), systemic scleroderma, Sjogren's syndrome (SS) and systemic lupus erythematosus (SLE) have all been linked to MM and plasma cell dyscrasias (Table 2) [6,36–37]. Nonetheless, the association between MM and RA is rather weak according to several cohort studies and case reports [9,36–37]. Two recent meta-analyses did not find a statistically significant increase in the risk for MM in patients with RA [9,13]. However, both studies showed a high level of between-study heterogeneity ( $I^2 > 50\%$ ) that could have affected their conclusions. A subgroup analysis of the study by Shen et al. [13] revealed that patients with RA are more likely to be diagnosed with subsequent MM (relative risk [RR] = 1.32). McShane et al. [9] found an increased risk of MM in patients with RA (RR = 1.18) as well, although they were not able to show statistical significance. In addition, several case-control studies found that there was an increased risk of developing MM after being diagnosed with RA [38–40]. The discrepancy between the studies could be due to reverse causality bias. Indeed, RA preceded the development of MM in case studies and most case reports in the literature [37–38]. Consequently, it is conceivable that prolonged antigenic stimulation present in RA could lead to the development of MM.

#### 5.2. Systemic lupus erythematosus

The association between SLE and lymphoproliferative disorders is well known. In a cohort study, nearly 11% of patients with MM were

**Table 2**  
Rheumatologic autoimmune disorders associated with multiple myeloma in the literature.

Disease	Proposed mechanism	Epidemiology	Therapy	References
RA	RA usually precedes MM; prolonged antigenic stimulation induced by RA can lead to MM.	Conflicting data	No change	[37–40]
SLE	Similar to RA In addition, defective immune surveillance in SLE may lead to uncontrolled clonal proliferation of plasma cells.	MM tends to be diagnosed at an earlier age.	No change	[41–43]
DM and PM	Chronic immune stimulation leading to B-cell clonal expansion	2.29 relative risk of developing plasma cell dyscrasias	No change	[45–49]
SS		IgG myeloma is the most common subtype.	SS symptoms may improve with MM therapy	[13,53–60]
AS	Unknown	Unknown	No change	[46,61–66]
LCV	Overexpression of IL-6 genes in MM may lead to development of LCV.	IgG myeloma is more prevalent than other subtypes.	No change	[67–73]

DM: dermatomyositis. HM: hematologic malignancy. IL-6: interleukin-6. MM: multiple myeloma. PM: polymyositis. RA: rheumatoid arthritis. SLE: systemic lupus erythematosus. SS: Sjogren's syndrome. AS: ankylosing spondylitis. LCV: leukocytoclastic vasculitis.

reported to have clinico-laboratory features of SLE [41]. In addition, increased prevalence of SLE in family members of patients with MM has also been reported [42]. Review of literature revealed more than a dozen cases of MM in patients with SLE [43]. In all of them, SLE either preceded or was diagnosed concurrently with MM. The median age of diagnosis of MM in patients with SLE was 45 years, which is younger than the median age of 64 years seen in the general population [44]. The pathophysiology underlying the association between SLE and MM is unclear. Similar to RA, it is plausible that prolonged antigenic stimulation present in SLE leads to development of MM. Conversely, defective immune surveillance in SLE may lead to selection of specific B-cell clones, thus leading to the development of MM.

### 5.3. Dermatomyositis and polymyositis

Dermatomyositis (DM) and polymyositis (PM) are associated with hematologic malignancies [45]. A recent retrospective cohort study of 4641 patients with MM/MGUS found that DM and PM are associated with an increased risk (relative risk = 2.29) of developing plasma cell dyscrasias [46]. Several researchers even reported cases of DM-related MM [47–48]. Similarly, a few case reports described PM associated with MM [49–50]. Unlike the situation in DM, the diagnosis of PM occurred either simultaneously or after the diagnosis of MM. Chronic immune stimulation that occurs in PM/DM is thought to cause T-cell and B-cell activation, thus leading to the development of certain hematologic malignancies including MM [51].

### 5.4. Sjogren's syndrome

There have been reports in literature linking Sjogren's syndrome (SS) and MM [6,13]. SS is a chronic autoimmune disease featuring a progressive lymphocytic proliferation and destruction of the salivary and lacrimal glands causing xerostomia and xerophthalmia. An increased risk of NHL and thyroid cancer has been reported in patients with SS [52]. Several cohort studies found an increased risk of MM and MGUS in patients with primary SS, while several reports described SS preceding MM [53–55]. In addition, there has been an increased incidence of free monoclonal light chains and proteins detected in serum and urine in patients with SS, with monoclonal IgG as the most frequent immunoglobulin detected [56–58]. Another study by Tomi et al. [59] found an increased risk of monoclonal gammopathy in patients with SS, where a longer duration and higher severity of SS correlated with the highest risk. Although exact mechanism remains unclear, chronic inflammation as a potential trigger for the development of MM is hypothesized [53]. Patients with concurrent SS and MM demonstrated clinical improvement of SS after treatment with thalidomide and dexamethasone [60]. This suggests a possible causal relationship between the two disorders.

### 5.5. Ankylosing spondylitis

Ankylosing spondylitis (AS) is an inflammatory rheumatic disease involving the axial skeleton. A retrospective cohort of over 4 million United States (US) white and black male veterans followed for 27 years found a significantly increased relative risk of 2.29 of developing MM and MGUS in subjects with AS [46]. Several reports describe development of MM in patients with longstanding AS [61–66]. Among those cases, one patient had IgA lambda and five patients had IgA kappa multiple myeloma. In all reported cases the diagnosis of AS preceded the diagnosis of MM. While the exact mechanism for this association is unclear, persistent plasma cell stimulation and activation in AS has been proposed as a potential trigger for IgA MM [61].

### 5.6. Leukocytoclastic vasculitis

Leukocytoclastic vasculitis (LCV) represents a small vessel vasculitis that may present as palpable purpura. Although data is limited on the relationship between vasculitides and MM, several studies suggested an association between the two. A case series by Bayer-Garner and Smoller [67] evaluated eight patients with concomitant MM and LCV. This study found that all patients had IgG myeloma associated with LCV. In contrast, several case-reports described IgA myeloma associated with LCV [68–72]. Another report describes a patient who developed MM, retinal vasculitis and temporal arteritis [73]. While the exact pathogenesis for the development of LCV in MM is unknown, some authors postulated that overexpression of IL-6 genes in MM may contribute to the development of LCV [67].

## 6. Autoimmune neurologic disorders in multiple myeloma

Several retrospective cohort studies have reported the presence of autoimmune neurologic disorders including myasthenia gravis (MG) and multiple sclerosis (MS) in patients with plasma cell dyscrasias, including MM (Table 3) [9,74–75]. One report described MM that developed in a patient suffering from MS for 26 years [76]. Similarly, a case of Waldenstrom's macroglobulinemia was described in a patient suffering from MS for 39 years [77]. Conversely, MS and peripheral demyelinating neuropathies have been described in patients with monoclonal gammopathies [78]. These findings suggest a possible association between monoclonal gammopathies and demyelinating neuropathies, which is thought to be due to shared genetic susceptibility. Indeed, one study demonstrated increased frequency of MS in relatives of 1317 MM patients [79].

Cases of coexistence of MG and MM in the literature are rare. In one case report, MG preceded the development of MM by 20 years [80]. In addition, MG was described in a patient with extramedullary plasmacytoma and in another patient with MM [81–82].

**Table 3**  
Neurologic and other autoimmune disorders associated with multiple myeloma in the literature.

Disease	Proposed mechanism	Epidemiology	Therapy	References
MG	MG usually precedes MM	Very rare	May improve with MM therapy	[74,75,80–82]
MS	Genetic susceptibility	Unknown	No change	[74–76,78,79]
MGN	Monoclonal immunoglobulin deposition	Unknown	May improve with MM therapy	[85]
IBD	Increased B-cell and plasma cell activation may lead to MM	Unknown	No change	[87,88]

IBD: inflammatory bowel disease. MG: myasthenia gravis. MGN: membranous glomerulonephritis. MM: multiple myeloma. MS: multiple sclerosis.

## 7. Immunomodulatory drugs and multiple myeloma

Published data have suggested that some agents used to treat autoimmune disorders might confer an increased risk of myeloma. In particular, a case-control study found a 5-, 3-, and 6-fold increased risk of developing multiple myeloma in women taking prednisone, insulin, and gout medications (e.g. sulphinyprazole and colchicine), respectively [1,9].

On the other hand, some multiple myeloma therapies can also lead to the development of autoimmune conditions. In 2009, for the first time, Dasanu and Alexandrescu reported a case of lenalidomide-induced aplastic anemia that resolved spontaneously after the discontinuation of lenalidomide [83]. In 2014, a retrospective study by Montefusco et al. [84] found a 4.3% absolute risk of autoimmune disorders in MM patients treated with lenalidomide. Most autoimmune conditions developed within six months of starting therapy. These diseases included ALHA, ITP, Evans syndrome, optic neuritis, autoimmune thyroiditis, polymyositis, and cutaneous vasculitis. In that study, autologous stem cell transplantation for multiple myeloma was also associated with a statistically significant increased risk of developing autoimmune disorders.

## 8. Other autoimmune disorders in multiple myeloma

Renal abnormalities such as tubular light-chain deposition disease, interstitial nephritis, primary amyloidosis and monoclonal deposition disease are well-recognized in patients with MM [85]. However, nephrotic syndrome is a rare presentation in MM. A case-series by Thachil et al. [86] describes two MM patients who developed membranous glomerulonephritis. Nephrotic syndrome resolved after the myeloma therapy, suggesting an association between MM and membranous glomerulonephritis. Monoclonal immunoglobulin deposition is thought to play a role in the pathogenesis of nephrotic syndrome in MM [86].

A large, retrospective cohort study of patients with multiple myeloma suggested that inflammatory bowel disease (IBD) may be associated with the development of MM [9] (Table 3). Minami et al. described instances of MM in patients with ulcerative colitis (UC) and Crohn's disease [87]. In both cases, MM developed during a long-term observation of patients with IBD. There have been nine additional reported cases of MM developing in the setting of IBD [88]. In these cases, the diagnosis of MM was made between 6–30 years after the diagnosis of IBD. While anti-TNF therapies (i.e. infliximab) could have played a role in the development of MM, only 3 of 9 patients were treated with such agents. This suggests that mechanisms involving increased B-cell activation might be responsible for the development of MM in IBD [88].

## 9. MGUS and autoimmunity

MGUS is known to precede MM, and carries an average 1% annual risk of progression to MM. Indeed, on a molecular level, MM is consistently preceded by MGUS [89]. Nonetheless, most cases of MGUS never progress to a full-blown MM. While the pathogenesis of MGUS and MM is still not well-understood, there is evidence that immune dysregulation and/or sustained immune stimulation may play a role in the development of these two hematologic entities [90]. A recent population-based study and a case-series showed clearly that several

immune-mediated conditions were associated with a significant risk of developing MGUS [91,92].

A recent meta-analysis demonstrated that autoimmune conditions were associated with a nearly 42% increase in risk of MGUS [9]. Similar to the situation in MM, patients with pernicious anemia display a significantly increased risk of developing MGUS [9]. Furthermore, this study found a non-significant association between ankylosing spondylitis and polymyositis/dermatomyositis with MGUS [9].

A study of United States veterans suggested that subjects with autoimmune conditions where autoantibodies are detectable are at increased risk of developing MGUS [46]. Furthermore, a recent population-based study found that personal or family history of autoimmune disease increases the risk of developing MGUS [91]. In that study, history of giant cell arteritis, polymyalgia rheumatica and rheumatoid arthritis was associated with a significantly increased risk of MGUS [91]. Two additional case-series demonstrated an increased prevalence of autoimmune axonal or peripheral demyelinating neuropathy in patients with MGUS [93,94].

In a recent prospective study, 15% patients with MGUS were found to have a preceding autoimmune disorder [95]. Sjogren's syndrome, polymyositis and vitiligo have been reported to precede the development of MGUS in three patients from Senegal [92]. Interestingly, their monoclonal components stabilized after the treatment of their autoimmune conditions. Another case series reported four patients with Sjogren's syndrome, Kikuchi disease, neuromyelitis optica and ankylosing spondylitis, respectively, who developed MGUS either coincidentally or up to 10 years after the diagnosis of the autoimmune condition [90].

Several studies have found that inflammatory/infectious conditions such as pneumonia, sepsis, meningitis and osteoarthritis increase the risk of developing MGUS and in some cases - of MM [46,91]. This suggests that an overwhelming inflammatory process can trigger the development of MGUS and myeloma. It had been proposed that infections can lead to a clonal proliferation by serving as a trigger for certain genetic translocations [96].

Taken together, these findings suggest that autoimmune diseases and inflammatory conditions may increase the risk of developing MGUS. As a result, chronic antigen stimulation may trigger the development of a plasma cell dyscrasia. Alternatively, there might be a common genetic or environmental susceptibility for developing both an autoimmune disease and a MGUS.

## 10. Discussion and conclusions

Patients with MM appear to be at increased risk for various autoimmune conditions. Nonetheless, information available in the literature on autoimmune conditions in patients with MM/MGUS consists largely of retrospective analyses of case series or isolated reports. This might limit the accuracy of our analysis. Some conclusions of our review might render an overestimation of the association between autoimmune conditions and MM due to the retrospective nature of most studies on this topic in the published literature. Presence of publication bias is another concern, reflecting the fact that studies reporting positive associations are more likely to be published than studies reporting negative associations. Finally, some associations between instances of autoimmunity and MM/MGUS could represent a mere coincidence.

Etiopathogenesis of autoimmune conditions and MM appears multifactorial and complex. Furthermore, insights from pathophysiology could explain the risk for both diseases. In most cases, development of an autoimmune condition precedes the development of MM. This echoes the hypothesis made by Rudolf Virchow who, in 1863, stated that the origin of cancer at different sites was due to chronic inflammation. Consequently, MM/MGUS could develop due to chronic inflammation in the setting of autoimmune disorders. Chronic antigenic stimulation of B-lymphocytes present in autoimmune disorders might eventually lead to clonal proliferation, and ultimately to MM. In addition, defective immune surveillance in autoimmunity may lead to pre-selection of specific B-cell clones, thus triggering development of MM. Moreover, some studies suggested shared genetic susceptibility for both conditions.

Many autoimmune diseases could be primary, and may play a role in the pathogenesis of MGUS/MM. Conversely, autoimmune conditions may develop after the diagnosis of MGUS/MM has been made. Future studies are needed to better understand the relationship between MM and autoimmune disorders. The autoimmune conditions can pose significant clinical problems for the MM patients and health care providers; therefore, a catalogue of this information is important to raise awareness and improve timely diagnosis and management.

### Transparency document

The Transparency document associated with this article can be found, in online version.

### Conflict of interest

The authors of this manuscript certify that they have NO affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers' bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.

### References

- [1] O. Landgren, Y. Zhang, S.H. Zahm, P. Inskip, T. Zheng, D. Baris, Risk of multiple myeloma following medication use and medical conditions: a case-control study in Connecticut women, *Cancer Epidemiol. Biomark. Prev.* 15 (12) (Dec 2006) 2342–2347.
- [2] R.A. Kyle, T.M. Therneau, S.V. Rajkumar, et al., A long-term study of prognosis in monoclonal gammopathy of undetermined significance, *N. Engl. J. Med.* 346 (8) (Feb 21, 2002) 564–569.
- [3] D.D. Alexander, P.J. Mink, H.O. Adami, et al., Multiple myeloma: a review of the epidemiologic literature, *Int. J. Cancer* 120 (Suppl. 12) (2007) 40–61.
- [4] C.A. Dasanu, Intrinsic and treatment-related immune alterations in chronic lymphocytic leukaemia and their impact for clinical practice, *Expert. Opin. Pharmacother.* 9 (9) (Jun 2008) 1481–1494.
- [5] J. Grabska, C.A. Dasanu, Autoimmune phenomena in untreated and treated marginal zone lymphoma, *Expert. Opin. Pharmacother.* 12 (15) (Oct 2011) 2369–2379.
- [6] A.L. Franks, J.E. Slansky, Multiple associations between a broad spectrum of autoimmune diseases, chronic inflammatory diseases and cancer, *Anticancer Res.* 32 (4) (Apr 2012) 1119–1136.
- [7] K.K. Thakur, N.B. Bolshette, C. Trandafir, et al., Role of toll-like receptors in multiple myeloma and recent advances, *Exp. Hematol.* 43 (3) (Mar 2015) 158–167.
- [8] P.J. Hengeveld, M.J. Kersten, B-cell activating factor in the pathophysiology of multiple myeloma: a target for therapy? *Blood Cancer J.* 5 (2015), e282.
- [9] C.M. McShane, L.J. Murray, O. Landgren, et al., Prior autoimmune disease and risk of monoclonal gammopathy of undetermined significance and multiple myeloma: a systematic review, *Cancer Epidemiol. Biomark. Prev.* 23 (2) (Feb 2014) 332–342.
- [10] E.F. Osserman, K. Takatsuki, Considerations regarding the pathogenesis of the plasmacytic dyscrasias, *Scand. J. Haematol.* 4 (Suppl) (1965) 28–49.
- [11] K.C. Soderberg, F. Jonsson, O. Winqvist, L. Hagmar, M. Feychting, Autoimmune diseases, asthma and risk of haematological malignancies: a nationwide case-control study in Sweden, *Eur. J. Cancer* 42 (17) (Nov 2006) 3028–3033.
- [12] R. Baz, C. Alemany, R. Green, M.A. Hussein, Prevalence of vitamin B12 deficiency in patients with plasma cell dyscrasias: a retrospective review, *Cancer* 101 (4) (Aug 15, 2004) 790–795.
- [13] K. Shen, G. Xu, Q. Wu, D. Zhou, J. Li, Risk of multiple myeloma in rheumatoid arthritis: a meta-analysis of case-control and cohort studies, *PLoS One* 9 (3) (2014), e91461.
- [14] A.W. Hsing, L.E. Hansson, J.K. McLaughlin, et al., Pernicious anemia and subsequent cancer: a population-based cohort study, *Cancer* 71 (3) (Feb 1, 1993) 745–750.
- [15] L.A. Brinton, G. Gridley, Z. Hrubeck, R. Hoover, J.F. Fraumeni Jr., Cancer risk following pernicious anaemia, *Br. J. Cancer* 59 (5) (May 1989) 810–813.
- [16] S. Friso, S.W. Choi, The potential cocarcinogenic effect of vitamin B12 deficiency, *Clin. Chem. Lab. Med.* 43 (10) (2005) 1158–1163.
- [17] B.A. Walker, C.P. Wardell, L. Chiecchio, et al., Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma, *Blood* 117 (2) (Jan 13, 2011) 553–562.
- [18] B. Pirofsky, Clinical aspects of autoimmune hemolytic anemia, *Semin. Hematol.* 13 (4) (Oct 1976) 251–265.
- [19] M. Friedland, P. Schaefer, Myelomatosis and hemolytic anemia. Hemolytic anemia, a rare complication of multiple myeloma, is successfully managed by splenectomy, *R. I. Med. J.* 62 (12) (Dec 1979) 469–471.
- [20] R. Kashyap, A. Singh, P. Kumar, Prevalence of autoimmune hemolytic anemia in multiple myeloma: a prospective study, *Asia Pac. J. Clin. Oncol.* (Sep 22, 2014).
- [21] A.W. Hauswirth, C. Skrabbs, C. Schutzinger, A. Gaiger, K. Lechner, U. Jager, Autoimmune hemolytic anemias, Evans' syndromes, and pure red cell aplasia in non-Hodgkin lymphomas, *Leuk. Lymphoma* 48 (6) (Jun 2007) 1139–1149.
- [22] G. Vaiopoulos, D. Kyriakou, H. Papadaki, P. Fessas, G.D. Eliopoulos, Multiple myeloma associated with autoimmune hemolytic anemia, *Haematologica* 79 (3) (May–Jun 1994) 262–264.
- [23] K. Sawada, N. Fujishima, M. Hirokawa, Acquired pure red cell aplasia: updated review of treatment, *Br. J. Haematol.* 142 (4) (Aug 2008) 505–514.
- [24] Y. Lv, W. Qian, Treatment of pure red cell aplasia associated with multiple myeloma with bicalcic gammopathy using cyclosporine A: a case report, *Int. J. Clin. Exp.* 8 (1) (2015) 1498–1500.
- [25] C.C. So, W.W. Choi, Y.L. Kwong, Pure red cell aplasia associated with CD20+ myeloma: complete remission with rituximab, *Ann. Hematol.* 92 (10) (Oct 2013) 1425–1426.
- [26] K.S. Sarathy, R. Ramakrishna, W.W. Baig, A. Manoharan, Acquired pure red cell aplasia in patients with plasma cell neoplasm and long term remission with bortezomib therapy, *J. Hematol. Malig.* 3 (2) (2014) 37.
- [27] V. Gupta, U.M. Hegde, R. Parameswaran, A.C. Newland, Multiple myeloma and immune thrombocytopenia, *Clin. Lab. Haematol.* 22 (4) (Aug 2000) 239–242.
- [28] J.D. Verdirame, J.R. Feagler, J.R. Commers, Multiple myeloma associated with immune thrombocytopenic purpura, *Cancer* 56 (5) (Sep 1, 1985) 1199–1200.
- [29] D.B. Cines, H. Liebman, R. Stasi, Pathobiology of secondary immune thrombocytopenia, *Semin. Hematol.* 46 (1 Suppl 2) (Jan 2009) S2–14.
- [30] S. Yonekura, T. Nagao, S. Arimori, M. Miyaji, K. Ogoshi, Y. Tsutsumi, Evans' syndrome associated with gastric plasmacytoma: case report and a review of the literature, *Jpn. J. Med.* 29 (5) (Sep–Oct 1990) 512–515.
- [31] Y. Yi, G.S. Zhang, F.J. Gong, J.J. Yang, Multiple myeloma complicated by Evans syndrome, *Intern. Med. J.* 39 (6) (Jun 2009) 421–422.
- [32] A. Palumbo, J. Blade, M. Boccadoro, et al., How to manage neutropenia in multiple myeloma, *Clin. Lymphoma Myeloma Leuk.* 12 (1) (Feb 2012) 5–11.
- [33] M. Akhtari, B. Curtis, E.K. Waller, Autoimmune neutropenia in adults, *Autoimmun. Rev.* 9 (1) (Sep 2009) 62–66.
- [34] M.R. Aryal, V.R. Bhatt, P. Tandra, et al., Autoimmune neutropenia in multiple myeloma and the role of clonal T-cell expansion: evidence of cross-talk between B-cell and T-cell lineages? *Clin. Lymphoma Myeloma Leuk.* 14 (1) (Feb 2014) e19–e23.
- [35] K.A. Shastri, B.M. O'Connor, G.L. Logue, D.S. Shimm, P.K. Rustagi, Light chain composition of serum granulocyte binding immunoglobulins, *Am. J. Hematol.* 37 (3) (Jul 1991) 167–172.
- [36] A. Alexopoulou, S.P. Dourakis, A. Apostolopoulou, A. Kandyli, H. Pandelidaki, A.J. Archimandritis, Light chain multiple myeloma in a patient with long-standing rheumatoid arthritis, *Clin. Rheumatol.* 24 (6) (Nov 2005) 669–670.
- [37] M.R. Ardalan, M.M. Shoja, Multiple myeloma presented as acute interstitial nephritis and rheumatoid arthritis-like polyarthritides, *Am. J. Hematol.* 82 (4) (Apr 2007) 309–313.
- [38] M. Eriksson, Rheumatoid arthritis as a risk factor for multiple myeloma: a case-control study, *Eur. J. Cancer* 29A (2) (1993) 259–263.
- [39] F. Inoue, T. Ohno, H. Furukawa, A case of rheumatoid arthritis associated with multiple myeloma, *Nihon Rinsho Meneki Gakkai Kaishi* 19 (1) (Feb 1996) 94–99.
- [40] S. Katusic, C.M. Beard, L.T. Kurland, J.W. Weis, E. Bergstralh, Occurrence of malignant neoplasms in the Rochester, Minnesota, rheumatoid arthritis cohort, *Am. J. Med.* 78 (1 A) (Jan 21 1985) 50–55.
- [41] S. Bernatsky, J.F. Boivin, L. Joseph, et al., An international cohort study of cancer in systemic lupus erythematosus, *Arthritis Rheum.* 52 (5) (May 2005) 1481–1490.
- [42] M.S. Linet, J.K. McLaughlin, S.D. Harlow, J.F. Fraumeni, Family history of autoimmune disorders and cancer in multiple myeloma, *Int. J. Epidemiol.* 17 (3) (Sep 1988) 512–513.
- [43] K. Okoli, F. Irani, W. Horvath, Multiple myeloma and systemic lupus erythematosus in a young woman, *J. Clin. Rheumatol.* 15 (6) (Sep 2009) 292–294.
- [44] R.A. Kyle, E.D. Remstein, T.M. Therneau, et al., Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma, *N. Engl. J. Med.* 356 (25) (Jun 21 2007) 2582–2590.
- [45] I. Marie, L. Guillemin, J.F. Menard, et al., Hematological malignancy associated with polymyositis and dermatomyositis, *Autoimmun. Rev.* 11 (9) (Jul 2012) 615–620.
- [46] L.M. Brown, G. Gridley, D. Check, O. Landgren, Risk of multiple myeloma and monoclonal gammopathy of undetermined significance among white and black male United States veterans with prior autoimmune, infectious, inflammatory, and allergic disorders, *Blood* 111 (7) (Apr 1 2008) 3388–3394.

- [47] J.H. Talbott, Acute dermatomyositis-polymyositis and malignancy, *Semin. Arthritis Rheum.* 6 (4) (May 1977) 305–360.
- [48] P.J. Zilko, R.L. Dawkins, Amyloidosis associated with dermatomyositis and features of multiple myeloma. The progression of amyloidosis associated with corticosteroid and cytotoxic drug therapy, *Am. J. Med.* 59 (3) (Sep 1975) 448–452.
- [49] A. Islam, K. Myers, D.M. Cassidy, S.F. Ho, M. De Silva, Malignancy: case report: muscle involvement in multiple myeloma: report of a patient presenting clinically as polymyositis, *Hematology* 4 (2) (1999) 123–125.
- [50] I. Colombo, M.E. Fruguglietti, L. Napoli, et al., IgD multiple myeloma paraproteinemia as a cause of myositis, *Neurol. Res. Int.* 2010 (2010) 808474.
- [51] S. Zampieri, M. Valente, N. Adami, et al., Polymyositis, dermatomyositis and malignancy: a further intriguing link, *Autoimmun. Rev.* 9 (6) (Apr 2010) 449–453.
- [52] N.A. Pavlidis, A.A. Drosos, C. Papadimitriou, N. Talal, H.M. Moutsopoulos, Lymphoma in Sjogren's syndrome, *Med. Pediatr. Oncol.* 20 (4) (1992) 279–283.
- [53] I. Tazi, M. Rachid, S. Benchekroun, Sjogren's syndrome associated with multiple myeloma, *Singap. Med. J.* 49 (8) (Aug 2008) e215–e216.
- [54] T. Ota, A. Wake, S. Eto, T. Kobayashi, Sjogren's syndrome terminating with multiple myeloma, *Scand. J. Rheumatol.* 24 (5) (1995) 316–318.
- [55] Y. Liang, Z. Yang, B. Qin, R. Zhong, Primary Sjogren's syndrome and malignancy risk: a systematic review and meta-analysis, *Ann. Rheum. Dis.* 73 (6) (Jun 2014) 1151–1156.
- [56] H.M. Moutsopoulos, A.D. Steinberg, A.S. Fauci, H.C. Lane, N.M. Papadopoulos, High incidence of free monoclonal lambda light chains in the sera of patients with Sjogren's syndrome, *J. Immunol.* 130 (6) (Jun 1983) 2663–2665.
- [57] H.M. Moutsopoulos, R. Costello, A.A. Drosos, A.K. Mavridis, N.M. Papadopoulos, Demonstration and identification of monoclonal proteins in the urine of patients with Sjogren's syndrome, *Ann. Rheum. Dis.* 44 (2) (Feb 1985) 109–112.
- [58] P. Brito-Zeron, M. Ramos-Casals, N. Nardi, et al., Circulating monoclonal immunoglobulins in Sjogren syndrome: prevalence and clinical significance in 237 patients, *Medicine* 84 (2) (Mar 2005) 90–97.
- [59] A.L. Tomi, R. Belkhir, G. Nocturne, et al., Monoclonal gammopathy and risk of lymphoma and multiple myeloma in patients with primary Sjogren's syndrome, *Arthritis Rheumatol.* (Dec 4, 2015).
- [60] U.P. Kulkarni, Y.A. Gokhale, P.M. Raut, R.R. Dargad, An unusual cause for sicca syndrome, *J. Postgrad. Med.* 57 (2) (Apr–Jun 2011) 129–130.
- [61] T.W. O'Neill, B.J. Harrison, A.L. Yin, P.J. Holt, Ankylosing spondylitis associated with IgA lambda chain myeloma, *Br. J. Rheumatol.* 36 (3) (Mar 1997) 401–402.
- [62] S.M. Lam, H.H. Ho, P. Dunn, S.F. Luo, Association of ankylosing spondylitis with IgA-multiple myeloma: report of a case and pathogenetic considerations. *Taiwan yi xue hui za zhi*, *J. Formos. Med. Assoc.* 88 (7) (Jul 1989) 726–728.
- [63] A.P. Blanc, J.A. Gastaut, G. Sebahoun, Y. Carcassonne, Association for ankylosing spondylarthritis multiple myeloma. A case history (author's transl), *Sem. Hop.* 55 (27–30) (Sep 8–15, 1979) 1335–1337.
- [64] H.-I. Moon, H.-J. Chang, J.-E. Kim, H.-Y. Ko, S.-H. Ann, C.-K. Min, The association between multiple myeloma and ankylosing spondylitis: a report of two cases, *Korean J. Hematol.* 44 (3) (2009) 182–187.
- [65] M. Gualandi, F. Trotta, M. Faggioli, A. Vanini, M.C. Tassinari, Association of non-secreting myeloma and ankylosing spondylitis. Considerations on a clinical case, *Minerva Med.* 72 (39) (Oct 13 1981) 2631–2637.
- [66] E. Perez-Pampin, J. Campos, J. Blanco, M. Perez-Encinas, A. Mera, Oligo-secretory myeloma in a patient with ankylosing spondylitis, *Rheumatol. Int.* 30 (9) (Jul 2010) 1227–1229.
- [67] I.B. Bayer-Garner, B.R. Smoller, Leukocytoclastic (small vessel) vasculitis in multiple myeloma, *Clin. Exp. Dermatol.* 28 (5) (Sep 2003) 521–524.
- [68] N.B. Sanchez, I.F. Canedo, P.E. Garcia-Patos, P.P. de Unamuno, A.V. Benito, A.M. Pascual, Paraneoplastic vasculitis associated with multiple myeloma, *J. Eur. Acad. Dermatol. Venereol.* 18 (6) (Nov 2004) 731–735.
- [69] P. Jain, P. Kumar, P.M. Parikh, Multiple myeloma with paraneoplastic leukocytoclastic vasculitis, *Indian J. Cancer* 46 (2) (Apr–Jun 2009) 173–174.
- [70] P. Peterlin, T. Ponge, N. Blin, P. Moreau, M. Hamidou, C. Agard, Paraneoplastic cutaneous leukocytoclastic vasculitis disclosing multiple myeloma: a case report, *Clin. Lymphoma Myeloma Leuk.* 11 (4) (Aug 2011) 373–374.
- [71] M. Carlesimo, A. Narcisi, D. Orsini, et al., Angiomatoid lesions (leukocytoclastic vasculitis) as paraneoplastic manifestations of multiple myeloma IgA lambda, *Eur. J. Dermatol.* 21 (2) (Mar–Apr 2011) 260–261.
- [72] M. Witzens, T. Moehler, K. Neben, et al., Development of leukocytoclastic vasculitis in a patient with multiple myeloma during treatment with thalidomide, *Ann. Hematol.* 83 (7) (Jul 2004) 467–470.
- [73] Y.K. Keung, C. Yung, J.W. Wong, F. Shah, E. Cobos, Association of temporal arteritis, retinal vasculitis, and xanthomatosis with multiple myeloma: case report and literature review, *Mayo Clin. Proc.* 73 (7) (Jul 1998) 657–660.
- [74] K. Hemminki, X. Liu, A. Forsti, J. Ji, J. Sundquist, K. Sundquist, Effect of autoimmune diseases on incidence and survival in subsequent multiple myeloma, *J. Hematol. Oncol.* 5 (2012) 59.
- [75] R.A. Kyle, M.A. Gertz, T.E. Witzig, et al., Review of 1027 patients with newly diagnosed multiple myeloma, *Mayo Clin. Proc.* 78 (1) (Jan 2003) 21–33.
- [76] S.H. Tsung, Monoclonal gammopathy associated with multiple sclerosis, *Ann. Clin. Lab. Sci.* 8 (6) (Nov–Dec 1978) 472–475.
- [77] S. Deftereou, D. Farmakis, A. Papadogianni, et al., Waldenstrom's macroglobulinemia developing in a patient with multiple sclerosis: coincidence or association? *Mult. Scler.* 10 (5) (Oct 2004) 598–600.
- [78] S. Trefouret, J.P. Azulay, J. Pouget, J. Boucraut, G. Serratrice, Late-onset multiple sclerosis and serum monoclonal gammopathy: an incidental association? *Rev. Neurol.* 152 (8–9) (Aug–Sep 1996) 554–556.
- [79] S. Grufferman, H.J. Cohen, E.S. Delzell, M.C. Morrison, S.C. Schold Jr., J.O. Moore, Familial aggregation of multiple myeloma and central nervous system diseases, *J. Am. Geriatr. Soc.* 37 (4) (Apr 1989) 303–309.
- [80] H. Urbanska-Rys, E. Robak, R. Kordek, et al., Multiple myeloma in a patient with systemic lupus erythematosus, myasthenia gravis and non-familial diffuse palmoplantar keratoderma, *Leuk. Lymphoma* 45 (9) (Sep 2004) 1913–1918.
- [81] A.R. Ahmed, A.J. Marchbank, A.G. Nicholson, A.C. Wotherspoon, G.P. Ladas, Extramedullary plasmacytoma presenting with myasthenia gravis and mediastinal mass, *Ann. Thorac. Surg.* 70 (4) (Oct 2000) 1390–1392.
- [82] L.P. Rowland, E.F. Osserman, W.B. Scharfman, R.F. Balsam, S. Ball, Myasthenia gravis with a myeloma-type, gamma-G (IgG) immunoglobulin abnormality, *Am. J. Med.* 46 (4) (Apr 1969) 599–605.
- [83] C.A. Dasanu, D.T. Alexandrescu, A case of severe aplastic anemia secondary to treatment with lenalidomide for multiple myeloma, *Eur. J. Haematol.* 82 (3) (Mar 2009) 231–234.
- [84] V. Montefusco, M. Galli, F. Spina, et al., Autoimmune diseases during treatment with immunomodulatory drugs in multiple myeloma: selective occurrence after lenalidomide, *Leuk. Lymphoma* 55 (9) (Sep 2014) 2032–2037.
- [85] J.J. Montseny, D. Kleinknecht, A. Meyrier, et al., Long-term outcome according to renal histological lesions in 118 patients with monoclonal gammopathies, *Nephrol. Dial. Transplant.* 13 (6) (Jun 1998) 1438–1445.
- [86] J. Thachil, W. Sadik, H. Shawki, K.A. Abraham, Membranous glomerulonephritis—an under-reported histological finding in multiple myeloma, *Nephrol. Dial. Transplant.* 24 (5) (May 2009) 1695–1696.
- [87] A. Minami, A. Iwai, Y. Watanabe, et al., Two cases of inflammatory bowel disease with multiple myeloma, *J. Gastroenterol.* 34 (5) (Oct 1999) 629–633.
- [88] G.J. Reynolds, K.A. Annis, W.J. de Villiers, Review article: multiple myeloma and inflammatory bowel disease, *Dig. Dis. Sci.* 52 (9) (Sep 2007) 2022–2028.
- [89] O. Landgren, R.A. Kyle, S.V. Rajkumar, From myeloma precursor disease to multiple myeloma: new diagnostic concepts and opportunities for early intervention, *Clin. Cancer Res.* 17 (6) (Mar 15, 2011) 1243–1252.
- [90] S.Y. Cho, H.S. Yang, Y.L. Jeon, et al., A case series of autoimmune diseases accompanied by incidentally diagnosed monoclonal gammopathy: is there a link between the two diseases? *Int. J. Rheum. Dis.* 17 (6) (Jul 2014) 635–639.
- [91] E.K. Lindqvist, L.R. Goldin, O. Landgren, et al., Personal and family history of immune-related conditions increase the risk of plasma cell disorders: a population-based study, *Blood* 118 (24) (Dec 8 2011) 6284–6291.
- [92] S. Diallo, F.S. Ndiaye, A. Pouye, et al., Monoclonal gammopathy of undetermined significance and autoimmune disease: description of three cases in Senegal, *Med. Trop.* 68 (1) (Feb 2008) 65–68.
- [93] V. Jonsson, H.D. Schroder, W. Trojborg, T.S. Jensen, E. Hippe, H.M. Mork, Autoimmune reactions in patients with M-component and peripheral neuropathy, *J. Intern. Med.* 232 (2) (Aug 1992) 185–191.
- [94] V. Jonsson, B. Svendsen, S. Vorstrup, et al., Multiple autoimmune manifestations in monoclonal gammopathy of undetermined significance and chronic lymphocytic leukemia, *Leukemia* 10 (2) (Feb 1996) 327–332.
- [95] M. Kwok, N. Mary, E. Manasanch, et al., Role of immune-related conditions in smoldering myeloma and MGUS, ASCO Annual Meeting Proceedings, vol. 30 No. 15, suppl., 2012.
- [96] R. Fonseca, B. Barlogie, R. Bataille, et al., Genetics and cytogenetics of multiple myeloma: a workshop report, *Cancer Res.* 64 (4) (2004) 1546–1558.